Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer
C Chen, Z Chen, D Chen, B Zhang… - Journal of …, 2015 - journals.sagepub.com
C Chen, Z Chen, D Chen, B Zhang, Z Wang, H Le
Journal of International Medical Research, 2015•journals.sagepub.comObjective To investigate the effect of gemcitabine plus cisplatin chemotherapy on the
percentage of CD4+ CD25+ FOXP3+ and CD8+ CD28–regulatory T cells (Tregs) in the
peripheral blood of patients with nonsmall-cell lung cancer (NSCLC). Methods Peripheral
blood was taken from patients with NCSLC (before and after chemotherapy) and control
subjects with nonmalignant disease. The percentages of CD4+ CD25+ FOXP3+ and CD8+
CD28–Tregs were analysed using flow cytometry. Results Patients (n= 40) had significantly …
percentage of CD4+ CD25+ FOXP3+ and CD8+ CD28–regulatory T cells (Tregs) in the
peripheral blood of patients with nonsmall-cell lung cancer (NSCLC). Methods Peripheral
blood was taken from patients with NCSLC (before and after chemotherapy) and control
subjects with nonmalignant disease. The percentages of CD4+ CD25+ FOXP3+ and CD8+
CD28–Tregs were analysed using flow cytometry. Results Patients (n= 40) had significantly …
Objective
To investigate the effect of gemcitabine plus cisplatin chemotherapy on the percentage of CD4+CD25+FOXP3+ and CD8+CD28– regulatory T cells (Tregs) in the peripheral blood of patients with nonsmall-cell lung cancer (NSCLC).
Methods
Peripheral blood was taken from patients with NCSLC (before and after chemotherapy) and control subjects with nonmalignant disease. The percentages of CD4+CD25+FOXP3+ and CD8+CD28– Tregs were analysed using flow cytometry.
Results
Patients (n = 40) had significantly higher CD4+CD25+FOXP3+ and CD8+CD28– percentages than control subjects (n = 24). CD4+CD25+FOXP3+ and CD8+CD28– percentages increased with tumour progression, fell significantly after chemotherapy, but remained significantly higher than control values.
Conclusions
CD4+CD25+FOXP3+ and CD8+CD28– Treg percentages were higher in patients with NSCLC than control subjects, and increased in line with tumour progression. Percentages of CD4+CD25+FOXP3+ and CD8+CD28– Tregs were significantly reduced following gemcitabine plus cisplatin chemotherapy.
Sage Journals